Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 2:00 p.m. ET.
A live webcast of the fireside chat may be accessed at the “Events & Presentations” section of the Company’s website at http://investors.kezarlifesciences.com/events . Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company bringing novel treatments to patients with rare autoimmune diseases and cancer. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead development candidate, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis. Additionally, KZR-261, the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway, is undergoing IND-enabling activities. For more information, visit www.kezarlifesciences.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005196/en/
Celia Economides
SVP, Strategy & External Affairs
IR@kezarbio.com
Argot Partners
(212)-600-1902
kezar@argotpartners.com